Hereditary Angioedema: Diagnosis, Clinical Implications, and Pathophysiology

Area of Science:

• Immunology
• Genetics
• Pharmacology

Background:

• Hereditary angioedema (HAE) is an autosomal dominant disorder linked to C1 esterase inhibitor (C1-INH) gene mutations.
• It affects approximately 1 in 50,000 individuals globally, with distinct types including those with C1-INH deficiency (Type I/II) and normal C1-INH activity (formerly Type III).
• Recent guidelines advocate for classifying HAE with normal C1-INH based on specific genetic mutations like KNG1, PLG, MYOF, HS3ST6, F12, and ANGPT1.

Purpose of the Study:

• To provide a comprehensive overview of Hereditary Angioedema (HAE).
• To detail the clinical presentation and diagnostic approaches for HAE.
• To review current and emerging therapeutic strategies for HAE management.

Main Methods:

• Literature review of hereditary angioedema.
• Analysis of genetic mutations associated with HAE subtypes.
• Summary of clinical manifestations and diagnostic markers.
• Compilation of treatment options including acute management and prophylaxis.

Main Results:

• HAE presents with non-pitting edema and abdominal pain, typically emerging in early adulthood.
• Diagnosis involves assessing C1-INH levels, bradykinin levels, and potentially C4 and D-dimer.
• Treatment strategies encompass C1-INH infusions, receptor antagonists, kallikrein inhibitors for acute attacks, and C1-INH for prophylaxis.

Conclusions:

• HAE is a complex disorder with diverse genetic underpinnings and clinical presentations.
• Accurate diagnosis relies on a combination of clinical suspicion and laboratory findings.
• Effective management involves tailored acute and prophylactic therapies to improve patient outcomes.